Código QR (código de barras bidimensional)

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Abstract Background Fremanezumab has demonstrated to be effective, safe, and tolerated in the prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials (RCTs). Real-life studies are needed to explore drug effects in unselected patients in routine circumstances and to p...

ver descrição completa

Na minha lista:
Principais autores: Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo FilippiBonassi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri, for the FRIEND-Study Group
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2022-04-01
coleção:The Journal of Headache and Pain
Assuntos:
Fremanezumab
Migraine treatment
CGRP monoclonal antibody
Real-world
Predictor
Acesso em linha:https://doi.org/10.1186/s10194-022-01396-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados